ZA202001561B - Human cytomegalovirus immunogenic composition - Google Patents
Human cytomegalovirus immunogenic compositionInfo
- Publication number
- ZA202001561B ZA202001561B ZA2020/01561A ZA202001561A ZA202001561B ZA 202001561 B ZA202001561 B ZA 202001561B ZA 2020/01561 A ZA2020/01561 A ZA 2020/01561A ZA 202001561 A ZA202001561 A ZA 202001561A ZA 202001561 B ZA202001561 B ZA 202001561B
- Authority
- ZA
- South Africa
- Prior art keywords
- immunogenic composition
- human cytomegalovirus
- cytomegalovirus immunogenic
- human
- composition
- Prior art date
Links
- 241000701024 Human betaherpesvirus 5 Species 0.000 title 1
- 230000002163 immunogen Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17306179 | 2017-09-13 | ||
| PCT/EP2018/074369 WO2019052975A1 (en) | 2017-09-13 | 2018-09-11 | IMMUNOGENIC COMPOSITION AGAINST HUMAN CYTOMEGALOVIRUS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202001561B true ZA202001561B (en) | 2021-07-28 |
Family
ID=60782111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2020/01561A ZA202001561B (en) | 2017-09-13 | 2020-03-12 | Human cytomegalovirus immunogenic composition |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US11524069B2 (enExample) |
| EP (1) | EP3681534A1 (enExample) |
| JP (2) | JP7770767B2 (enExample) |
| KR (2) | KR20250006307A (enExample) |
| CN (1) | CN111344009A (enExample) |
| AU (1) | AU2018331874B2 (enExample) |
| BR (1) | BR112020004747A2 (enExample) |
| CA (1) | CA3075207A1 (enExample) |
| IL (1) | IL273120B2 (enExample) |
| MX (1) | MX2020002810A (enExample) |
| SG (1) | SG11202002174SA (enExample) |
| WO (1) | WO2019052975A1 (enExample) |
| ZA (1) | ZA202001561B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020004747A2 (pt) | 2017-09-13 | 2020-09-24 | Sanofi Pasteur | composição imunogênica de citomegalovírus humano |
| JP7179872B2 (ja) * | 2018-12-10 | 2022-11-29 | Ｋｍバイオロジクス株式会社 | サイトメガロウイルスの先天性感染を予防又は治療するためのワクチン |
| TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽 |
| EP4237085A1 (en) * | 2020-10-28 | 2023-09-06 | Sanofi Pasteur | Liposomes containing tlr4 agonist, preparation and uses thereof |
| WO2024218752A1 (en) * | 2023-04-21 | 2024-10-24 | Instar Technologies A.S. | Pharmaceutical composition for vaccination against cytomegalovirus infections |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4987237A (en) | 1983-08-26 | 1991-01-22 | Ribi Immunochem Research, Inc. | Derivatives of monophosphoryl lipid A |
| US6100064A (en) * | 1984-04-06 | 2000-08-08 | Chiron Corporation | Secreted viral proteins useful for vaccines and diagnostics |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US5547834A (en) | 1988-01-29 | 1996-08-20 | Chiron Corporation | Recombinant CMV neutralizing proteins |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| KR920701453A (ko) | 1989-03-17 | 1992-08-11 | 미리엄 디. 멕코나헤이 | 유전자발현의 외부조절 |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| EP0761231B1 (en) | 1992-06-25 | 2000-01-12 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine composition containing adjuvants |
| US5362865A (en) | 1993-09-02 | 1994-11-08 | Monsanto Company | Enhanced expression in plants using non-translated leader sequences |
| US5693506A (en) | 1993-11-16 | 1997-12-02 | The Regents Of The University Of California | Process for protein production in plants |
| US20020102562A1 (en) | 1995-05-24 | 2002-08-01 | Pasteur Merieux Serums Et Vaccines S.A. | Recombinant CMV neutralizing proteins |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6835721B2 (en) | 1999-02-01 | 2004-12-28 | Eisai Co., Ltd. | Immunomodulatory compounds and methods of use thereof |
| US20040006242A1 (en) | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
| GB0023008D0 (en) | 2000-09-20 | 2000-11-01 | Glaxo Group Ltd | Improvements in vaccination |
| WO2004060396A2 (en) | 2002-12-27 | 2004-07-22 | Chiron Corporation | Immunogenic compositions containing phospholpid |
| FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
| CA2654563A1 (en) * | 2006-06-07 | 2007-12-21 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
| ATE549031T1 (de) * | 2007-09-21 | 2012-03-15 | Sanofi Pasteur | Impfstoffzusammensetzung zur prävention von cmv- infektionen |
| MX2010008799A (es) | 2008-03-05 | 2010-09-07 | Sanofi Pasteur | Proceso para estabilizar una composicion de vacuna que contiene adyuvante. |
| LT2437753T (lt) | 2009-06-05 | 2016-12-12 | Infectious Disease Research Institute | Sintetiniai gliukopiranozillipidų adjuvantai ir juos turinčios vakcinų kompozicijos |
| CA2814386C (en) * | 2010-10-11 | 2019-08-20 | Novartis Ag | Antigen delivery platforms |
| AR083454A1 (es) | 2010-10-15 | 2013-02-27 | Glaxosmithkline Biolog Sa | Antigeno de citomegalovirus |
| WO2012141984A1 (en) * | 2011-04-08 | 2012-10-18 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| EP2729168A2 (en) * | 2011-07-06 | 2014-05-14 | Novartis AG | Immunogenic compositions and uses thereof |
| MX378747B (es) | 2012-07-06 | 2025-03-10 | Glaxosmithkline Biologicals S A Star | Complejos de proteínas de citomegalovirus. |
| AU2013293570B2 (en) * | 2012-07-27 | 2019-05-23 | City Of Hope | An MVA vaccine for delivery of a UL128 complex and preventing CMV infection |
| US20150359879A1 (en) * | 2012-10-30 | 2015-12-17 | Redvax Gmbh | Recombinant particle based vaccines against human cytomegalovirus infection |
| US20170119874A1 (en) * | 2014-04-23 | 2017-05-04 | Institute For Research In Biomedicine | Human cytomegalovirus vaccine compositions and method of producing the same |
| EP3139953A1 (en) | 2014-05-08 | 2017-03-15 | Pfizer Inc. | Means and methods for treating cmv |
| EP3031822A1 (en) | 2014-12-08 | 2016-06-15 | Novartis AG | Cytomegalovirus antigens |
| WO2017044895A2 (en) * | 2015-09-10 | 2017-03-16 | City Of Hope | MVA-gH/gL-PC VACCINE DERIVED ANTIBODIES NEUTRALIZING HUMAN CYTOMEGALOVIRUS INFECTIVITY AND METHODS THEREOF |
| MA46316A (fr) * | 2015-10-22 | 2021-03-24 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
| HRP20250077T1 (hr) * | 2016-06-17 | 2025-03-28 | Boehringer Ingelheim Vetmedica Gmbh | Nove imunogene formulacije koje sadrže ravne ili razgranate polimerne adjuvante poliakrilne kiseline |
| BR112020004747A2 (pt) | 2017-09-13 | 2020-09-24 | Sanofi Pasteur | composição imunogênica de citomegalovírus humano |
-
2018
- 2018-09-11 BR BR112020004747-3A patent/BR112020004747A2/pt not_active Application Discontinuation
- 2018-09-11 JP JP2020514916A patent/JP7770767B2/ja active Active
- 2018-09-11 KR KR1020247040905A patent/KR20250006307A/ko active Pending
- 2018-09-11 CA CA3075207A patent/CA3075207A1/en active Pending
- 2018-09-11 AU AU2018331874A patent/AU2018331874B2/en active Active
- 2018-09-11 IL IL273120A patent/IL273120B2/en unknown
- 2018-09-11 SG SG11202002174SA patent/SG11202002174SA/en unknown
- 2018-09-11 WO PCT/EP2018/074369 patent/WO2019052975A1/en not_active Ceased
- 2018-09-11 CN CN201880072392.9A patent/CN111344009A/zh active Pending
- 2018-09-11 US US16/646,894 patent/US11524069B2/en active Active
- 2018-09-11 KR KR1020207010481A patent/KR20200051778A/ko not_active Ceased
- 2018-09-11 EP EP18765127.8A patent/EP3681534A1/en active Pending
- 2018-09-11 MX MX2020002810A patent/MX2020002810A/es unknown
-
2020
- 2020-03-12 ZA ZA2020/01561A patent/ZA202001561B/en unknown
- 2020-10-15 US US17/071,817 patent/US11207403B2/en active Active
-
2022
- 2022-12-08 US US18/077,713 patent/US20230277655A1/en active Pending
-
2023
- 2023-11-24 JP JP2023198785A patent/JP2024026160A/ja active Pending
-
2025
- 2025-01-14 US US19/020,003 patent/US20250228933A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020002810A (es) | 2020-07-21 |
| WO2019052975A1 (en) | 2019-03-21 |
| RU2020113253A (ru) | 2021-10-18 |
| IL273120B1 (en) | 2023-06-01 |
| WO2019052975A9 (en) | 2020-04-09 |
| US11524069B2 (en) | 2022-12-13 |
| AU2018331874B2 (en) | 2022-06-02 |
| US20200276301A1 (en) | 2020-09-03 |
| RU2020113253A3 (enExample) | 2021-11-17 |
| JP2024026160A (ja) | 2024-02-28 |
| US11207403B2 (en) | 2021-12-28 |
| JP7770767B2 (ja) | 2025-11-17 |
| SG11202002174SA (en) | 2020-04-29 |
| JP2020533354A (ja) | 2020-11-19 |
| IL273120A (en) | 2020-04-30 |
| US20250228933A1 (en) | 2025-07-17 |
| BR112020004747A2 (pt) | 2020-09-24 |
| EP3681534A1 (en) | 2020-07-22 |
| NZ763438A (en) | 2025-03-28 |
| KR20250006307A (ko) | 2025-01-10 |
| IL273120B2 (en) | 2023-10-01 |
| US20210023202A1 (en) | 2021-01-28 |
| KR20200051778A (ko) | 2020-05-13 |
| CA3075207A1 (en) | 2019-03-21 |
| AU2018331874A1 (en) | 2020-04-30 |
| CN111344009A (zh) | 2020-06-26 |
| US20230277655A1 (en) | 2023-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273541A (en) | formulations | |
| IL273282A (en) | Niraprib formulations | |
| IL269630A (en) | Niraprib formulations | |
| IL269621A (en) | Niraparib formulations | |
| GB201711635D0 (en) | Immunogenic composition | |
| EP3294409C0 (en) | CORTICAL VISION PROSTHESIS | |
| ZA202001561B (en) | Human cytomegalovirus immunogenic composition | |
| GB201610599D0 (en) | Immunogenic Composition | |
| IL271603A (en) | Immunogenic preparations | |
| GB201707189D0 (en) | Novel formulations | |
| GB201802339D0 (en) | Immunogenic composition | |
| EP3397277C0 (en) | IMMUNOGENIC COMPOSITION | |
| GB201711637D0 (en) | Immunogenic composition | |
| GB201707188D0 (en) | Novel formulations | |
| GB2562241B (en) | Vaccine compositions | |
| GB201614485D0 (en) | Immunogenic composition | |
| GB201707187D0 (en) | Novel formulations | |
| GB201604755D0 (en) | Immunogenic compositions | |
| GB201703529D0 (en) | Vaccine composition | |
| GB201803692D0 (en) | Immunogenic composition | |
| GB201718251D0 (en) | Vaccine Compositions | |
| GB201911959D0 (en) | Immunogenic compositions and uses therefor | |
| HK40034236A (zh) | 人巨细胞病毒免疫原性组合物 | |
| GB201805338D0 (en) | Cosmetic formulations | |
| SG11202004167XA (en) | Immunogenic compositions and uses therefor |